secondary outcome measures

secondary outcome measures

The outcome measures in a clinical trial that provide information on therapeutic effects of secondary importance, side effects or tolerability. Data on secondary outcomes are used to evaluate additional effects of the intervention not included in the primary outcome measure.
References in periodicals archive ?
Secondary outcome measures include reduction in disability and radiographic improvement.
The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12.
Secondary outcome measures include the achievement of at least a 50% reduction from baseline in mean monthly migraine days across the double-blind treatment phase, and the mean number of rescue medication days per month, each as measured over the course of the double-blind, treatment phase.
As for secondary outcome measures, there was no difference in rates of postpartum hemorrhage or uterotonic administration between the two groups (P = .99 for both).
The secondary outcome measures were time to tolerate oral intake and development of local and systemic complications.
The secondary outcome measures of mean change in Health Assessment Questionnaire Disability Index (HAQ-DI), patients global assessment, physician global assessment, and ACR CRISS scores were statistically significant or showed numerical results favoring abatacept over placebo: mean decrease in HAQ-DI, -0.17 vs.
To assess the effectiveness of surgical decompression radiologically, APdiameter of the spinal canal was measured at the intervertebral disc level of the involved spinal segment on computed axial T2-weighted MRI sections (Siemens, Erlangen, Germany), pre-operatively and at a minimum 1 year post-operatively.19-21 MWD, surgical complications, duration of surgical procedure and LOS were the secondary outcome measures.
Key secondary outcome measures were mean change from baseline in subjective sleep efficiency and subjective wake after sleep onset after six months of placebo- controlled treatment.
Linear mixed models were used to investigate changes in primary and secondary outcome measures from pretreatment to posttreatment, and pretreatment to 3-month follow-up.
There were no differences between groups in a secondary outcome measures, including positive provocative stress testing and changes in UDI, PCI-I, Incontinence Severity Index, and quality-of-life measures.
Secondary outcome measures included changes in the Aberrant Behavior Checklist (ABC) and the Social Responsiveness Scale (SRS).